Marimba

Marimba Bio is a preclinical-stage biotechnology company specializing in the development of in vivo gene editing therapies. The company’s proprietary platform is engineered to facilitate the precise insertion of large genetic payloads into the human genome, overcoming the size constraints of traditional viral vectors and first-generation CRISPR tools. By enabling the integration of full-length genes, Marimba Bio seeks to provide permanent, curative solutions for patients with complex genetic disorders. The company is headquartered in San Francisco and is backed by prominent life science investors including ARCH Venture Partners and GV. Their mission centers on expanding the reach of genomic medicine through highly efficient and site-specific gene delivery. Marimba Bio's approach aims to address a wide range of indications that require the replacement or addition of large functional genes.